Please Wait
Applying Filters...
menu
    • menu
    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Aurigene is a global leader in accelerating drug innovation through discovery, development & manufacturing.

    Virtual Booth

    Contact Supplier

    Midas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-06

    Virtual Booth

    Contact Supplier

    Menu

    Uproleselan

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Apollomics Announces Phase 3 Trial Results for Uproleselan in AML
    Apollomics Announces Phase 3 Trial Results for Uproleselan in AML

    20 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/20/3000556/0/en/Apollomics-Announces-Top-line-Results-for-Phase-3-Bridging-Trial-of-Uproleselan-in-China-in-Patients-with-Relapsed-or-Refractory-Acute-Myeloid-Leukemia.html

    GLOBENEWSWIRE
    20 Dec 2024
    Share Share
    GlycoMimetics: Pivotal Phase 3 Results Of Uproleselan In R/R AML
    GlycoMimetics: Pivotal Phase 3 Results Of Uproleselan In R/R AML

    04 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240604811237/en

    BUSINESSWIRE
    04 Jun 2024
    Share Share
    GlycoMimetics KOL Event On Uproleselan Phase 3 Data In R/R AML
    GlycoMimetics KOL Event On Uproleselan Phase 3 Data In R/R AML

    29 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240529592940/en

    BUSINESSWIRE
    29 May 2024
    Share Share
    GlycoMimetics reports Phase 3 results for Uproleselan in AML.
    GlycoMimetics reports Phase 3 results for Uproleselan in AML.

    06 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240506092613/en

    BUSINESSWIRE
    06 May 2024
    Share Share
    Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan
    Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan

    03 Jan 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/01/03/2803135/0/en/Apollomics-Completes-Enrollment-in-Phase-3-Bridging-Study-of-Uproleselan-in-Chinese-Patients-with-Relapsed-Refractory-Acute-Myeloid-Leukemia.html

    GLOBENEWSWIRE
    03 Jan 2024
    Share Share
    GlycoMimetics Announces Independent Presentations on Uproleselan
    GlycoMimetics Announces Independent Presentations on Uproleselan

    10 Dec 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231210360401/en

    BUSINESSWIRE
    10 Dec 2023
    Share Share